Jay Edelberg - Articles and news items

Sanofi and Regeneron report positive top-line results with alirocumab from first Phase 3 study of a PCSK9 inhibitor for LDL cholesterol reduction

Industry news / 16 October 2013 / Sanofi

Alirocumab monotherapy reduced “bad” cholesterol three times more than ezetimibe…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+